These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 35057002)

  • 1. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines.
    Halwani AA; Balkhi B; Alamoudi AA; Almozain NH; Alajmi AM; Noorwali A; Badr MY; Noor AO; Bagalagel A; Tawfik EA
    Saudi Pharm J; 2023 Aug; 31(8):101674. PubMed ID: 37448843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
    Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
    Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artificial intelligence aids in development of nanomedicines for cancer management.
    Tan P; Chen X; Zhang H; Wei Q; Luo K
    Semin Cancer Biol; 2023 Feb; 89():61-75. PubMed ID: 36682438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics.
    Choi YH; Han HK
    J Pharm Investig; 2018; 48(1):43-60. PubMed ID: 30546919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
    Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
    Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Commission-supported development of targeted nanomedicines: did MediTrans make a difference?
    Storm G; Aime S
    Ther Deliv; 2011 Jul; 2(7):861-4. PubMed ID: 22833900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Nanomedicines for Cancer Treatment.
    do Nascimento T; Todeschini AR; Santos-Oliveira R; de Souza de Bustamante Monteiro MS; de Souza VT; Ricci-Júnior E
    Curr Pharm Des; 2020; 26(29):3579-3600. PubMed ID: 32186271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine: a pharma perspective.
    Brown PD; Patel PR
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):125-30. PubMed ID: 25196070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues affecting nanomedicines on the way from the bench to the market.
    Longo JPF; Mussi S; Azevedo RB; Muehlmann LA
    J Mater Chem B; 2020 Dec; 8(47):10681-10685. PubMed ID: 33155000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and challenges in the translation of cancer nanomedicines.
    Tong F; Wang Y; Gao H
    Curr Opin Biotechnol; 2024 Feb; 85():103045. PubMed ID: 38096768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
    Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
    Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Taiwan's strategies for regulating nanotechnology-based pharmaceuticals harmonized with international considerations.
    Guo JW; Lee YH; Huang HW; Tzou MC; Wang YJ; Tsai JC
    Int J Nanomedicine; 2014; 9():4773-83. PubMed ID: 25342901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting endocytosis for nanomedicines.
    Akinc A; Battaglia G
    Cold Spring Harb Perspect Biol; 2013 Nov; 5(11):a016980. PubMed ID: 24186069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.